Access the full text.
Sign up today, get DeepDyve free for 14 days.
JM Kane (2010)
10.31887/DCNS.2010.12.3/jkaneDialogues Clin Neurosci, 12
B Costall (1978)
10.1016/0028-3908(78)90090-4Neuropharmacology, 17
DD Miller (2004)
Atypical antipsychotics: sleep, sedation, and efficacyPrim Care Companion J Clin Psychiatry, 6
A Becker, G Grecksch (2004)
Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validityProgress in Neuropsychopharmacol Biological Psychiatr, 28
GR Dawson, CM Heyes, SD Iversen (1992)
Pharmacological mechanisms and animal models of cognitionBehav Pharmacol, 3
ML Draper, DS Stutes, NJ Maples, DL Velligan (2009)
Cognitive adaptation training for outpatients with schizophreniaJ Clin Psychol, 65
F Kukla, R Gold (1999)
Negative schizophrenic symptoms and their detectionFortschr Neurol Psychiatr, 59
S Lipper (1976)
Psychosis in patient on bromocriptine and levodopa with carbidopaLancet, 2
SP Mahadik (1996)
10.1016/0920-9964(95)00049-6Schizophrenia Res, 19
OM Dean, M Buuse, AI Bush, DL Copolov, F Ng, S Dodd, M Berk (2009)
A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practiceCurr Med Chem, 16
XH Deng (2014)
10.4236/aad.2014.32009Advances Alzheimer’s Disease, 3
AT Eduviere (2015)
10.1016/j.lfs.2015.04.007Life Sci, 132
B Halliwell (2006)
10.1111/j.1471-4159.2006.03907.xJ Neurochemistr, 97
DC Hoffman (1995)
10.1007/BF02246184Psychopharmacol (Berlin), 120
V Bubeníková-Valesová (2008)
10.1016/j.neubiorev.2008.03.012Neurosci Biobehav Rev, 32
TA Lesh (2011)
10.1038/npp.2010.156Neuropsychopharmacology, 36
BKY Bitanihirwe, TW Woo (2011)
Oxidative stress in schizophrenia: an integrated approachNeurosci Biobehav Rev, 35
B Uttara, AW Singh, P Zamboni, RT Mahajan (2009)
Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic optionsCurr Neuropharmacol, 7
AM Johnson, DM Loew, JM Vigouret (1976)
Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and l-dopaBr J Pharmacol, 56
AK Malhotra (1997)
10.1016/S0893-133X(97)00036-5Neuropsychopharmacology, 17
S Shukla, WJ Turner, G Newman (1985)
Bromocriptine-related psychosis and treatmentBiological Psychiatr, 20
B Halliwell (2006)
Oxidative stress and neurodegeneration: where are we now?J Neurochemistr, 97
RE Brown (1999)
10.1023/A:1021694307672Behaviour Genetic, 26
PE Mullen (2006)
Schizophrenia and violence: from correlations to preventive strategiesAdv Psychiat Treat, 12
M Zhang, Z Zhao, L He, C Wan (2010)
A meta-analysis of oxidative stress markers in schizophreniaSci China Life Sci, 53
E Candelario-Jalil, SM Al-Dalain, R Castillo, G Martínez, OS León (2001)
Selective vulnerability to kainate-induced oxidative damage in different rat brain regionsJ Appl Toxicol, 21
TA Lesh, TA Niendam, MJ Minzenberg, CS Carter (2011)
Cognitive control deficits in schizophrenia: mechanisms and meaningNeuropsychopharmacology, 36
G Keilhoff, A Becker, G Grecksch, G Wolf, HG Bernstein (2004)
Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophreniaNeuroscience, 126
V Adam-Vizi (1982)
10.1016/0006-2952(82)90106-XRole of lipid peroxidation Biochem Pharmacol, 34
AK Malhotra, DA Pinals, CM Adler, I Elman, A Clifton, D Pickar, A Breier (1997)
Ketamine- induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic- free schizophrenicsNeuropsychopharmacology, 17
MS Moron, JW Depierre, B Mannervik (1979)
Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liverBiochim Biophys Acta, 582
M Zhang (2010)
10.1007/s11427-010-0013-8Sci China Life Sci, 53
A Becker (2004)
10.1016/j.pnpbp.2004.06.019Progress in Neuropsychopharmacol Biological Psychiatr, 28
S Umukoro, AT Eduviere, AC Aladeokin (2012)
Anti-aggressive activity of methyl jasmonate and the probable mechanism of its action in micePharmacol, Biochem & Behav, 101
V Casadesus (2006)
10.1016/j.bbadis.2006.01.008Biochimica Biophysica Acta, 1762
F Kukla (1999)
10.1055/s-2007-1000680Fortschr Neurol Psychiatr, 59
OM Dean (2009)
10.2174/092986709788803060Curr Med Chem, 16
XH Deng, M Li, W Ai, L He, D Lu, PR Patrylo, H Cai, X Luo, ZX Li, X-X Yan (2014)
Lipolysaccharide-induced neuroinflammation is associated with Alzheimer-like amyloidogenic axonal pathology and dendritic degeneration in ratsAdvances Alzheimer’s Disease, 3
AT Eduviere (2016)
10.1007/s11064-016-2050-6Neurochem Res, 41
S Lipper (1976)
10.1016/S0140-6736(76)91816-XLancet, 2
AM Johnson (1976)
10.1111/j.1476-5381.1976.tb06959.xBr J Pharmacol, 56
SP Mahadik, S Mukherjee (1996)
Free radical pathology and antioxidant defense in schizophrenia: a reviewSchizophrenia Res, 19
KL Davis (1991)
10.1176/ajp.148.11.1474Am J Psychiat, 148
HP Misra, I Fridovich (1972)
The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutaseJ Biol Chem, 247
M Chatterjee, V Rajkumar, G Surajit, P Gautam (2012)
Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in miceNeuropharmacology, 63
G Keilhoff (2004)
10.1016/j.neuroscience.2004.03.039Neuroscience, 126
B Costall, SCG Hui, RJ Naylor (1978)
Correlation between multitest and single test catalepsy assessmentNeuropharmacology, 17
BKY Bitanihirwe (2011)
10.1016/j.neubiorev.2010.10.008Neurosci Biobehav Rev, 35
M Bourin, L Poisson, C Larousse (1986)
Piracetam interaction with neuroleptics in psychopharmacological testsNeuropsychobiology, 19
KL Davis, RS Kahn, KO Grant, M Davidson (1991)
Dopamine in schizophrenia: a new review and conceptualizationAm J Psychiat, 148
KA Sinha (1971)
Colorimetric assay of catalaseAnal Biochem, 147
S Shukla (1985)
10.1016/0006-3223(85)90062-9Biological Psychiatr, 20
AT Eduviere, S Umukoro, OA Adeoluwa, IA Omogbiya, OM Aluko (2016)
Possible methyl mechanisms involved in attenuation of lipopolysaccharide-induced memory deficits by jasmonate in miceNeurochem Res, 41
JM Kane, CU Correll (2010)
Pharmacologic treatment of schizophreniaDialogues Clin Neurosci, 12
E Candelario-Jalil (2001)
10.1002/jat.768J Appl Toxicol, 21
K Kuroda, N Inoue, Y Ito, K Kubota, A Sugimoto, T Kakuda, T Fushiki (2005)
Sedative effects of the jasmine tea odor and (R)-(−)-linalool, one of its major odor components on autonomic nerve activity and mood statesEur J Appl Physiol, 95
GR Dawson (1992)
10.1097/00008877-199208000-00003Behav Pharmacol, 3
K Kuroda (2005)
10.1007/s00421-005-1402-8Eur J Appl Physiol, 95
B Uttara (2009)
10.2174/157015909787602823Curr Neuropharmacol, 7
AT Eduviere, S Umukoro, AO Aderibigbe, AM Ajayi, FA Adewole (2015)
Methyl jasmonate enhances memory performance through inhibition of oxidative stress and acetylcholinesteras activity in miceLife Sci, 132
PE Mullen (2006)
10.1192/apt.12.4.239Adv Psychiat Treat, 12
V Bubeníková-Valesová, J Horácek, M Vrajová, C Höschl (2008)
Models of schizophrenia in humans and animals based on inhibition of NMDA receptorsNeurosci Biobehav Rev, 32
S Umukoro (2012)
10.1016/j.pbb.2011.12.015Pharmacol, Biochem & Behav, 101
V Adam-Vizi, A Seregi (1982)
Receptor independent stimulatory effect of noradrenaline on Na+/K+-ATPase in rat brain homogenateRole of lipid peroxidation Biochem Pharmacol, 34
C Fendri, A Mechri, G Khiari, A Othman, A Kerkeni, L Gaha (2006)
Oxidative stress involvement in schizophrenia pathophysiology: a reviewEnceephale, 32
DC Hoffman, H Donovan (1995)
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liabilityPsychopharmacol (Berlin), 120
HP Misra (1972)
10.1016/S0021-9258(19)45228-9J Biol Chem, 247
M Bourin (1986)
10.1159/000118305Neuropsychobiology, 19
M Chatterjee (2012)
10.1016/j.neuropharm.2012.05.041Neuropharmacology, 63
RE Brown, SC Corey, AK Mooren (1999)
Differences in measures of exploration and fear in MHC congenic C578/61 and B6-H-2K miceBehaviour Genetic, 26
V Casadesus, KM Webber, CS Atwood, MA Pappolla, G Perry, RL Bowen, MA Smith (2006)
Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic miceBiochimica Biophysica Acta, 1762
C Fendri (2006)
10.1016/S0013-7006(06)76151-6Enceephale, 32
F Sams-Dodd (1998)
Effects of continuous D-amphetamine and phencyclidineadministration on social behaviour, stereotyped behaviour, and locomotoractivity in ratsNeuropsychopharmacology, 19
MS Moron (1979)
10.1016/0304-4165(79)90289-7Biochim Biophys Acta, 582
ML Draper (2009)
10.1002/jclp.20612J Clin Psychol, 65
Psychosis is a chronic neuropsychiatric disorder that affects millions of individuals worldwide and impairs the quality of life and productivity of the patients. The clinical efficacy of antipsychotic drugs has been compromised by adverse effects, relapse, and therapeutic failures, thus necessitating search for alternative agents. Methyl jasmonate (MJ) is a bioactive compound reported to have beneficial effects in various neurological disorders. This study was undertaken to investigate the antipsychotic-like effects of MJ in mice. Male Swiss mice were pretreated intraperitoneally with MJ (25–100 mg/kg) or vehicle (10 mL/kg) 60 min prior to bromocriptine (5 mg/kg) or acute injection of ketamine (10 mg/kg). Thereafter, each mouse was observed for stereotype behaviors for 2 min at 10, 15, 20, 30, and 45 min post-bromocriptine injection. Another set of mice received MJ (25–100 mg/kg) or vehicle (10 mL/kg) 60 min after chronic ketamine injection (20 mg/kg, i.p) once daily for 14 consecutive days. Afterwards, locomotor activity and memory function in this sequence were evaluated using open field and Y-maze tests. The levels of malondialdehyde (MDA) and glutathione (GSH) and activity of catalase and superoxide dismutase (SOD) in the brain were determined. MJ significantly inhibited stereotypy behavior induced by bromocriptine or acute ketamine injection, which suggest antipsychotic-like activity. It also attenuated hyper-locomotion and memory deficits induced by chronic injection of ketamine in mice. The increased oxidative stress as shown by the altered brain levels of MDA, GSH, and activity of antioxidant enzymes induced by chronic injection of ketamine was reduced by MJ. Taken together, these findings suggest that MJ demonstrated antipsychotic-like property via mechanism related to its antioxidant property and interference with dopaminergic neurotransmission.
Naunyn-Schmiedeberg's Archives of Pharmacology – Springer Journals
Published: Jun 13, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.